Home > Cardiology > ESC 2020 > Late-Breaking Science > Antisense ANGPTL3 lowers triglycerides

Antisense ANGPTL3 lowers triglycerides

Presented By
Prof. Daniel Gaudet, University of Montréal, Canada
ESC 2020
Reduction of ANGPTL3 mRNA levels with antisense oligonucleotide vupanorsen significantly lowered plasma triglyceride levels and other atherogenic lipoproteins in diabetic patients with hepatic steatosis and mild hypertriglyceridaemia. In addition, vupanorsen had a favourable safety and tolerability profile. Prof. Daniel Gaudet (University of Montréal, Canada) presented the results of the multicentre, double-blind, placebo-controlled, dose-ranging phase 2 study [1]. Type 2 diabetes patients (n=105) with hepatic steatosis and fasting triglyceride levels >150 mg/dL were included in 3 dosing strategy cohorts (both dose and timing were variables). Within each cohort, participants were randomised 3:1 to vupanorsen or placebo. The primary endpoint was percentage change from baseline in fasting triglyceride levels at week 24. The primary outcome was met. In the pooled placebo group, triglyceride change increased by a mean of 16%, whereas trigly...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on